US20060134087A1
(en)
*
|
1988-09-02 |
2006-06-22 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as hNE inhibitors
|
US7078383B2
(en)
*
|
1988-09-02 |
2006-07-18 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as HNE inhibitors
|
US5750373A
(en)
*
|
1990-12-03 |
1998-05-12 |
Genentech, Inc. |
Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
|
ATE529444T1
(de)
*
|
1994-01-11 |
2011-11-15 |
Dyax Corp |
Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
WO1995020401A1
(en)
|
1994-01-31 |
1995-08-03 |
Trustees Of Boston University |
Polyclonal antibody libraries
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US5786328A
(en)
*
|
1995-06-05 |
1998-07-28 |
Genentech, Inc. |
Use of kunitz type plasma kallikrein inhibitors
|
US5780265A
(en)
*
|
1995-06-05 |
1998-07-14 |
Genentech, Inc. |
Kunitz type plasma kallikrein inhibitors
|
US20030199450A1
(en)
*
|
2001-04-27 |
2003-10-23 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
US6242414B1
(en)
*
|
1995-06-07 |
2001-06-05 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
NZ331540A
(en)
|
1996-03-11 |
1999-10-28 |
Bayer Ag |
Human bikunin
|
US5876925A
(en)
*
|
1996-10-11 |
1999-03-02 |
The Trustees Of The University Of Pennsylvania |
Magnetically activated cell sorting for production of proteins
|
US5985543A
(en)
*
|
1996-10-11 |
1999-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for detection of antibody binding to cells
|
CA2279345A1
(en)
*
|
1997-01-31 |
1998-08-06 |
Human Genome Sciences, Inc. |
Tissue factor pathway inhibitor-3
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
EP1082431A2
(en)
*
|
1998-06-03 |
2001-03-14 |
Scios Inc. |
Protease inhibitor peptides
|
EP1100890A2
(en)
|
1998-07-27 |
2001-05-23 |
Genentech, Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
AU767975B2
(en)
|
1998-09-11 |
2003-11-27 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US20070140979A1
(en)
*
|
1998-12-22 |
2007-06-21 |
Bayer Aktiengesellschaft |
Method for accelerating the rate of mucociliary clearance
|
EP1374891B1
(en)
*
|
1998-12-22 |
2008-09-10 |
Bayer Aktiengesellschaft |
Method for accelerating the rate of mucociliary clearance
|
US6294648B1
(en)
*
|
1999-07-20 |
2001-09-25 |
Bayer Corporation |
Protein having proteinase inhibitor activity
|
US20030180714A1
(en)
*
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
EP1301612A2
(en)
*
|
2000-05-31 |
2003-04-16 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
US20020150594A1
(en)
*
|
2000-06-26 |
2002-10-17 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
US6989438B2
(en)
|
2000-09-04 |
2006-01-24 |
Debiopharm S.A. |
Process for the purification of EPI-HNE proteins
|
EP1184393A1
(en)
*
|
2000-09-04 |
2002-03-06 |
Debiopharm S.A. |
Process for the purification of EPI-HNE proteins
|
WO2002036158A1
(en)
|
2000-10-31 |
2002-05-10 |
Debiopharm S.A. |
Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
|
EP1201249A1
(en)
*
|
2000-10-31 |
2002-05-02 |
Debiopharm S.A. |
Suspension of EPI-HNE-4, dry powder aerosol derived therefrom, process of preparation thereof, pharmaceutical compositions containing said suspension or aerosol, and their uses
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US20030082630A1
(en)
*
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
WO2003062431A2
(en)
*
|
2002-01-23 |
2003-07-31 |
Debiopharm Sa |
Production of epi-hne-4 comprising reduction of improperly processed form
|
WO2003066078A1
(en)
*
|
2002-02-07 |
2003-08-14 |
Delta Biotechnology Limited |
Hiv inhibiting proteins
|
US20050222023A1
(en)
*
|
2002-02-07 |
2005-10-06 |
Hans-Peter Hauser |
Albumin-fused kunitz domain peptides
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP2298278B1
(en)
|
2002-06-07 |
2015-11-11 |
Dyax Corp. |
Prevention and reduction of blood loss and inflammatory response
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
EP1575515A4
(en)
*
|
2002-08-29 |
2007-08-08 |
Genentech Inc |
ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
|
US6989369B2
(en)
*
|
2003-02-07 |
2006-01-24 |
Dyax Corp. |
Kunitz domain peptides
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
CA3050564A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Dyax Corp. |
Poly-pegylated protease inhibitors
|
AU2004268144A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Dyax Corp. |
Modified protease inhibitors
|
US20050164301A1
(en)
*
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
WO2005094875A1
(en)
*
|
2004-03-31 |
2005-10-13 |
Coloplast A/S |
Use of epi-hne 1-4
|
US20060292554A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Genentech, Inc. |
Major coat protein variants for C-terminal and bi-terminal display
|
EP1771212A1
(en)
*
|
2004-07-16 |
2007-04-11 |
Coloplast A/S |
A wound care device
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
EP1835926A4
(en)
*
|
2004-11-22 |
2009-04-01 |
Dyax Corp |
PLASMINE-INHIBITING THERAPIES
|
US8841259B2
(en)
*
|
2005-02-24 |
2014-09-23 |
Joslin Diabetes Center |
Compositions and methods for treating vascular permeability
|
CA2597325A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
US8603782B2
(en)
*
|
2005-07-13 |
2013-12-10 |
Amgen Inc. |
Heat lysis production of proteins
|
ZA200800970B
(en)
|
2005-08-15 |
2009-10-28 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
GB0521404D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Ares Trading Sa |
Kunitz domain containing protein
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
AU2006342792A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
|
EP1981519B1
(en)
|
2005-12-29 |
2017-12-27 |
Dyax Corp. |
Protease inhibition
|
CA2924836A1
(en)
|
2005-12-29 |
2007-07-05 |
The Regents Of The University Of California |
Methods and compositions related to mutant kunitz domain i of tfpi-2
|
EP2050335A1
(en)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
EP2057465A4
(en)
|
2006-08-09 |
2010-04-21 |
Homestead Clinical Corp |
SPECIFIC ORGAN PROTEINS AND METHODS OF USE
|
EP2386655B1
(en)
|
2006-09-12 |
2014-11-19 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Adcc活性を増強させた抗体及びその製造方法
|
WO2008091692A2
(en)
*
|
2007-01-25 |
2008-07-31 |
Joslin Diabetes Center, Inc. |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
CA2696208A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Genzyme Corporation |
Treatment with kallikrein inhibitors
|
AU2008307145B2
(en)
*
|
2007-10-04 |
2014-07-10 |
Bionomics Limited |
Markers of endothelial cells and uses thereof
|
CN101186646B
(zh)
*
|
2007-10-26 |
2010-06-09 |
中国科学院昆明动物研究所 |
眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用
|
WO2009062102A2
(en)
|
2007-11-07 |
2009-05-14 |
Genentech, Inc. |
Compositions and methods for treatment of microbial disorders
|
US8575314B2
(en)
*
|
2008-06-20 |
2013-11-05 |
National University Corporation Okayama University |
Antibody against oxidized LDL/β2GPI complex and use of the same
|
US9182406B2
(en)
*
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
US20110275535A1
(en)
|
2008-12-16 |
2011-11-10 |
Novartis Ag |
Yeast Display Systems
|
JP5739816B2
(ja)
|
2008-12-19 |
2015-06-24 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
Tfpiインヒビターおよび使用法
|
AU2010203712A1
(en)
*
|
2009-01-06 |
2010-07-15 |
Dyax Corp. |
Treatment of mucositis with kallikrein inhibitors
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
MX2012006072A
(es)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
LT2521568T
(lt)
|
2010-01-06 |
2018-12-10 |
Dyax Corp. |
Plazmos kalikreiną surišantys baltymai
|
EP2536748B1
(en)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011115712A2
(en)
|
2010-03-19 |
2011-09-22 |
Baxter International Inc |
Tfpi inhibitors and methods of use
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
BR112013017080A8
(pt)
|
2011-01-06 |
2023-05-09 |
Dyax Corp |
Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
|
WO2012129347A1
(en)
|
2011-03-21 |
2012-09-27 |
Biodesy, Llc |
Classification of kinase inhibitors using nonlinear optical techniques
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
TW201840336A
(zh)
|
2011-08-01 |
2018-11-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
WO2013162654A1
(en)
|
2012-04-25 |
2013-10-31 |
Biodesy, Llc |
Methods for detecting allosteric modulators of proteins
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
CN104254541A
(zh)
|
2012-03-16 |
2014-12-31 |
弗·哈夫曼-拉罗切有限公司 |
改造的构象稳定蛋白质
|
RU2014141018A
(ru)
|
2012-03-16 |
2016-05-10 |
Ф. Хоффманн-Ля Рош Аг |
Способы лечения меланомы ингибиторами рак1
|
WO2013141965A1
(en)
|
2012-03-21 |
2013-09-26 |
Baxter International Inc. |
Tfpi inhibitors and methods of use
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
EP2708235A1
(en)
*
|
2012-09-17 |
2014-03-19 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Peptide antagonists of the vasopressin-2 receptor
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
CN105246511A
(zh)
|
2013-03-06 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
TR201809571T4
(tr)
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック, インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
MY183503A
(en)
|
2013-07-16 |
2021-02-23 |
Genentech Inc |
Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
JP6574431B2
(ja)
*
|
2014-02-24 |
2019-09-11 |
タケダ ゲー・エム・ベー・ハーTakeda GmbH |
Uti融合タンパク質
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
MX2016014504A
(es)
|
2014-05-05 |
2017-05-23 |
Regeneron Pharma |
Animales c5 y c3 humanizados.
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2015196070A1
(en)
|
2014-06-20 |
2015-12-23 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
CN106573060A
(zh)
|
2014-07-15 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
|
US11219670B2
(en)
|
2014-09-05 |
2022-01-11 |
The Johns Hopkins University |
Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
EP3237906B8
(en)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Attachment of proteins to interfaces for use in nonlinear optical detection
|
EP3273974A4
(en)
|
2015-03-26 |
2018-11-07 |
Women and Infants Hospital of Rhode Island Inc. |
Therapy for malignant disease
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
WO2016191397A1
(en)
|
2015-05-22 |
2016-12-01 |
Td2 Inc. |
Benzamide and active compound compositions and methods of use
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
EP3371211A4
(en)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
|
BR112018011622A2
(pt)
|
2015-12-11 |
2018-11-27 |
Dyax Corp |
método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
|
US10898483B2
(en)
|
2015-12-23 |
2021-01-26 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
WO2017189730A1
(en)
|
2016-04-26 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
CA3038331A1
(en)
|
2016-09-28 |
2018-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
SG11201907606XA
(en)
|
2017-02-27 |
2019-09-27 |
Regeneron Pharma |
Humanized model of kidney and liver disorders
|
MX2019012419A
(es)
|
2017-04-21 |
2019-12-05 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
EP3641752A4
(en)
|
2017-06-22 |
2021-03-17 |
Moonshot Pharma LLC |
CANCER TREATMENT METHODS USING COMPOSITIONS INCLUDING AMLEXANOX AND IMMUNOMODULATORS
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
US11427932B2
(en)
|
2019-04-17 |
2022-08-30 |
Impossible Foods Inc. |
Materials and methods for protein production
|
KR20220005568A
(ko)
|
2019-05-09 |
2022-01-13 |
제넨테크, 인크. |
항체의 제조 방법
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
US11725043B2
(en)
|
2020-03-05 |
2023-08-15 |
DiaMedica USA Inc. |
Ulinastatin polypeptides
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
CN112940095B
(zh)
*
|
2021-02-07 |
2022-04-15 |
西南大学 |
家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|